The Global mRNA Vaccine & Therapeutics Raw Material Market was Worth USD 37.53 Billion in 2021 and it is Expected to Reach USD 84.74 Billion at the End of 2028 with a CAGR of 12.34%.
have garnered significant attention in recent years, especially amidst the COVID-19 pandemic. These breakthroughs rely heavily on specialized raw materials sourced from leading companies in the biotechnology sector. This article explores the top 5 companies supplying raw materials for mRNA vaccine and therapeutics production, including Jena Bioscience, Thermo Fisher Scientific Inc., SBS Genetech, Lucigen, and Sigma Aldrich.
Jena Bioscience stands as a prominent player in providing high-quality raw materials essential for mRNA vaccine and therapeutics development. With a focus on nucleic acid research, the company offers a diverse range of products including mRNA synthesis kits, enzymes, and nucleotides. Jena Bioscience's commitment to innovation and quality control has positioned it as a trusted partner for researchers and pharmaceutical companies worldwide.
Thermo Fisher Scientific Inc.:
Thermo Fisher Scientific Inc. is a global leader in providing scientific solutions, including raw materials for mRNA vaccine and therapeutics manufacturing. The company offers a comprehensive portfolio of reagents, enzymes, and purification kits crucial for mRNA synthesis and purification processes. With its extensive distribution network and commitment to research and development, Thermo Fisher Scientific Inc. plays a pivotal role in advancing mRNA-based therapies.
SBS Genetech specializes in providing custom mRNA synthesis services and raw materials tailored to the specific needs of researchers and pharmaceutical companies. The company offers a wide range of nucleotides, modified bases, and purification reagents essential for mRNA vaccine and therapeutics production. SBS Genetech's expertise in mRNA technology and its dedication to quality make it a preferred choice for many in the industry.
Lucigen is renowned for its innovative solutions in molecular biology and genomics, including raw materials for mRNA-based applications. The company offers high-quality enzymes, polymerases, and purification kits optimized for mRNA synthesis and amplification. Lucigen's focus on cutting-edge research and customer satisfaction positions it as a key player in the mRNA vaccine and therapeutics raw material market.
Sigma Aldrich, a subsidiary of Merck KGaA, is a leading supplier of biochemicals, reagents, and raw materials for life science research and biopharmaceutical production. The company offers a comprehensive portfolio of products for mRNA synthesis, including nucleotides, enzymes, and purification columns. Sigma Aldrich's global presence and commitment to quality assurance make it a reliable partner for mRNA vaccine and therapeutics developers worldwide.
The top 5 companies in the mRNA vaccine and therapeutics raw material market – Jena Bioscience, Thermo Fisher Scientific Inc., SBS Genetech, Lucigen, and Sigma Aldrich – play indispensable roles in advancing the field of mRNA-based therapies. Their dedication to innovation, quality, and customer satisfaction underscores their significance in supporting the development and production of mRNA vaccines and therapeutics on a global scale.